Etanercept 50mg powder and solvent for solution for injection vials
Drugs used in rheumatic diseases and gout
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Etanercept
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Etanercept
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Part of the Enbrel brand family (generic: Etanercept)
MHRA licensed products
View all licensed products for Etanercept on the MHRA register
WHO defined daily dose (DDD)
7 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Clinical guidelines and formulary information
British National Formulary
Etanercept
Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.
NICE clinical guidance(15)
Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199)
Etanercept and efalizumab for treating moderate to severe plaque psoriasis (TA103)
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455)
Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373)
Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed (TA715)
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (TA195)
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (TA375)
Secukinumab for treating moderate to severe plaque psoriasis in children and young people (TA734)
Adalimumab for treating moderate to severe plaque psoriasis (TA146)
Golimumab for treating active non-radiographic axial spondyloarthritis (TA497)
Tofacitinib for treating juvenile idiopathic arthritis (TA735)
Ustekinumab for treating moderate to severe plaque psoriasis (TA180)
Tocilizumab for the treatment of rheumatoid arthritis (TA247)
Infliximab for treating moderate to severe plaque psoriasis (TA134)
Upadacitinib for treating severe rheumatoid arthritis (TA665)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & product information
Official product databases and supply status monitoring
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
102 hours
Mechanism
There are two distinct receptors for TNF (TNFRs), a 55 kilodalton protein (p55) and a 75 kilodalton protein (p75).
Food interactions
None known
Human targets
9 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
56.9%
Half-life
102 hours
[L14862]…
Protein binding
Volume of distribution
5.49 L
Metabolism
Clearance
160 mL
[L14862]…
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
[L14862][L45523]
It is also used to manage signs and symptoms of polyarticular idiopathic arthritis and Juvenile Psoriatic Arthritis in those aged 2 years and older. Etanercept is also used to manage the symptoms of psoriatic arthritis and ankylosing spondylitis.
[L48526]
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 1041 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
[A215352]
Another model in pediatric JIA patients showed an increased Ka of 0.05/h with a high mean interindividual variability of 215%.
[A215357]
Cmax after a single 25 mg subcutaneous dose of Enbrel is reported as 1.1 mcg/L with a Tmax of 69 h.
[L14862]
Cmax after repeated dosing is reported as 2.4 mcg/L in adult RA patients with a dosage of 25 mg twice weekly and 2.1 mcg in pediatric JIA patients with a dosage of 0.4 mg/kg twice weekly.
[L14862]
Population models have shown a mean half-life of 68 hours in healthy adults and 70.7-94.8 hours in pediatric JIA patients.
[A215657][A215357]
[A215352][A215357]
[L14862]
Population models predict a mean apparent clearance of 132 mL/h in healthy adults and 0.0576 L/h in pediatric JIA patients.
[A215657][A215357]
Proteins and enzymes this drug interacts with in the body
Impairs regulatory T-cells (Treg) function in individuals with rheumatoid arthritis via FOXP3 dephosphorylation. Up-regulates the expression of protein phosphatase 1 (PP1), which dephosphorylates the key 'Ser-418' residue of FOXP3, thereby inactivating FOXP3 and rendering Treg cells functionally defective .
PMID:23396208
Key mediator of cell death in the anticancer action of BCG-stimulated neutrophils in combination with DIABLO/SMAC mimetic in the RT4v6 bladder cancer cell line .
PMID:16829952 PMID:22517918 PMID:23396208
Induces insulin resistance in adipocytes via inhibition of insulin-induced IRS1 tyrosine phosphorylation and insulin-induced glucose uptake. Induces GKAP42 protein degradation in adipocytes which is partially responsible for TNF-induced insulin resistance (By similarity).
Plays a role in angiogenesis by inducing VEGF production synergistically with IL1B and IL6 .
PMID:12794819
Promotes osteoclastogenesis and therefore mediates bone resorption (By similarity)
PMID:9462508
In its heterotrimeric form with LTB binds to TNFRSF3/LTBR .
PMID:24248355
Lymphotoxin is produced by lymphocytes and is cytotoxic for a wide range of tumor cells in vitro and in vivo
Promotes phagocytosis of opsonized antigens
Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis. Isoform IIB2 does not trigger phagocytosis
ATC L04AB01
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Etanercept
Additional database identifiers
Drugs Product Database (DPD)
12032
HUGO Gene Nomenclature Committee (HGNC)
HGNC:11892
GenAtlas
TNF
GeneCards
TNF
GenBank Gene Database
M16441
GenBank Protein Database
339741
UniProt Accession
TNFA_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:6709
GenAtlas
LTA
GeneCards
LTA
GenBank Gene Database
X01393
GenBank Protein Database
34445
UniProt Accession
TNFB_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3613
GenAtlas
FCGR1A
GeneCards
FCGR1A
GenBank Gene Database
X14356
GenBank Protein Database
31332
UniProt Accession
FCGR1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3616
GenAtlas
FCGR2A
GeneCards
FCGR2A
GenBank Gene Database
M31932
GenBank Protein Database
182474
UniProt Accession
FCG2A_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3618
GenAtlas
FCGR2B
GeneCards
FCGR2B
GenBank Gene Database
U87560
GenBank Protein Database
4099445
UniProt Accession
FCG2B_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:15626
GenAtlas
FCGR2C
GeneCards
FCGR2C
GenBank Gene Database
X17652
GenBank Protein Database
32074
UniProt Accession
FCG2C_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3619
GenAtlas
FCGR3A
GeneCards
FCGR3A
GenBank Gene Database
X52645
GenBank Protein Database
31324
Guide to Pharmacology
3017
UniProt Accession
FCG3A_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3620
GenAtlas
FCGR3B
GeneCards
FCGR3B
GenBank Gene Database
X16863
GenBank Protein Database
31322
UniProt Accession
FCG3B_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:1241
GenAtlas
C1QA
GeneCards
C1QA
GenBank Gene Database
AF135157
GenBank Protein Database
4894854
UniProt Accession
C1QA_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:1242
GenAtlas
C1QB
GeneCards
C1QB
GenBank Gene Database
X03084
GenBank Protein Database
573114
UniProt Accession
C1QB_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:1245
GenAtlas
C1QC
GeneCards
C1QC
GenBank Gene Database
AF087892
GenBank Protein Database
33150626
UniProt Accession
C1QC_HUMAN
International reference pricing
Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.
Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.
Patent information
All patents expired, 3 expired
Source: DrugBank · CC BY-NC 4.0. Patent data sourced from national patent offices. Expiry dates may not reflect extensions, regulatory exclusivity periods, or legal challenges.
DrugBank citations
If you use DrugBank data in your research, please cite the following publications: